Predictors of local recurrence after rituximab-based chemotherapy alone in stage III and IV diffuse large b-cell lymphoma: Guiding decisions for consolidative radiation

Naresh Jegadeesh, Raj Rajpara, Natia Esiashvili, Zheng Shi, Yuan Liu, Derrick Okwan-Duodu, Christopher R. Flowers, Mohammad K. Khan

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Purpose The role of consolidative radiation therapy (RT) for stage III and IV diffuse large B-cell lymphoma (DLBCL) in the era of rituximab is not well defined. There is evidence that some patients with bulky disease may benefit, but patient selection criteria are not well established. We sought to identify a subset of patients who experienced a high local failure rate after receiving rituximab-based chemotherapy alone and hence may benefit from the addition of consolidative RT. Methods and Materials Two hundred eleven patients with stage III and IV DLBCL treated between August 1999 and January 2012 were reviewed. Of these, 89 had a complete response to systemic therapy including rituximab and received no initial RT. Kaplan-Meier analysis and Cox proportional hazards regression were performed, with local recurrence (LR) as the primary outcome. Results The median follow-up time was 43.9 months. Fifty percent of patients experienced LR at 5 years. In multivariate analysis, tumor ≥5 cm and stage III disease were associated with increased risk of LR. The 5-year LR-free survival was 47.4% for patients with ≥5-cm lesions versus 74.7% for patients with <5-cm lesions (P=.01). In patients with <5-cm tumors, the maximum standardized uptake value (SUVmax) was ≥15 in all patients with LR. The 5-year LR-free survival was 100% in SUV<15 versus 68.8% in SUV≥15 (P=.10). Conclusions Advanced-stage DLBCL patients with stage III disease or with disease ≥5 cm appear to be at an increased risk for LR. Patients with <5-cm disease and SUVmax ≥15 may be at higher risk for LR. These patients may benefit from consolidative RT after chemoimmunotherapy.

Original languageEnglish (US)
Pages (from-to)107-112
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Volume92
Issue number1
DOIs
StatePublished - May 1 2015
Externally publishedYes

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'Predictors of local recurrence after rituximab-based chemotherapy alone in stage III and IV diffuse large b-cell lymphoma: Guiding decisions for consolidative radiation'. Together they form a unique fingerprint.

Cite this